Startups
PRAGMA Therapeutics develops innovative and proprietary First-in-Class small molecule drugs specifically acting at the mGlu7 receptor for the treatment of Post-Traumatic Stress Disorder and hearing loss.
PRAGMA externalizes its R&D operations to CROs and academic partners, advancing its asset to first-in-man by 2018. A major transaction with a pharmaceutical company, through a licensing deal or M&A, is expected post-Phase 2 human proof-of-concept.
PRAGMA externalizes its R&D operations to CROs and academic partners, advancing its asset to first-in-man by 2018. A major transaction with a pharmaceutical company, through a licensing deal or M&A, is expected post-Phase 2 human proof-of-concept.
Overview
Employees
1-10
Founded date
2015
FAQ about PRAGMA Therapeutics
When was PRAGMA Therapeutics founded?
PRAGMA Therapeutics was founded in 2015.
Is PRAGMA Therapeutics still active?
Yes, PRAGMA Therapeutics is active; its latest activity on Parsers VC dates from Nov 14, 2023.